glp 1 hims GLP-1 ad battle: Ozempic and Wegovy maker on the & Hers Super Bowl ad Hims & Hers expands weight

And what trade-offs should be part of that conversation

The SURMOUNT-1 trial for tirzepatide showed average weight loss of 15 to 22 percent of body weight across the full study population

Su, Q.J., Ashenhurst, J.R., Xu, W

Such models do not adequately reflect the heterogeneity of human SUD populations, which differ in sex, age, comorbidities, and environmental context

Medically Reviewed | Updated: February 2026 Category: GLP-1 & Weight Loss | Reading Time: 8 min If youre preparing to start a GLP-1 receptor agonist whether thats semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or another agent in this class baseline lab testing is one of the most important steps you can take before your first dose